Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interferon-Free Hepatitis C Regimens Within Reach

Executive Summary

Much of the hep C wish list was on display at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13 – all-oral interferon-free drug combinations for hepatitis C, regimens that don’t require ribavirin, and the possibility of a one-pill, once-a-day cure – demonstrating the Gold Rush mentality in the hep C space as drug makers race to put the pieces together and grab a share of a burgeoning market.

Advertisement

Related Content

Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
Gilead Phase III Program For Two-Drug HCV Combo On Faster Pace Than Expected
Gilead Phase III Program For Two-Drug HCV Combo On Faster Pace Than Expected
Pipelines, Not the Bottom Line, Define 2012 For Investors
Korea’s Yuhan Corp. Has No Plans To Pursue Gilead’s Hep C Drug For Korea
Korea’s Yuhan Corp. Has No Plans To Pursue Gilead’s Hep C Drug For Korea
GSK’s Promacta Cleared For Use With Interferon In Hep C Patients
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel